What Is Tirzepatide? (Mounjaro, Zepbound)
Educational information only. This article does not diagnose, treat, cure or prevent any condition and is not medical advice. Decisions about which medication — if any — is appropriate for you are a matter for you and your qualified healthcare professional.
Tirzepatide is a dual GIP and GLP-1 receptor agonist — a medication that activates two gut hormone receptors rather than one. It is sold as Mounjaro (approved for type 2 diabetes) and Zepbound (approved for chronic weight management and, since December 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity). In head-to-head clinical trial data, tirzepatide has produced greater average weight loss than semaglutide — the leading GLP-1-only comparator.
What makes tirzepatide a "dual agonist"?
Most GLP-1 medications target a single receptor — the GLP-1 receptor. Tirzepatide was designed to activate two:
- The GLP-1 receptor — which reduces appetite, slows gastric emptying, and stimulates insulin release when blood sugar is elevated. See: What Is a GLP-1?
- The GIP receptor — GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone involved in insulin secretion, fat metabolism, and energy storage. The GIP pathway works through different mechanisms than GLP-1, and the combination is thought to produce complementary effects on appetite and metabolism.
Tirzepatide is not a GLP-1 receptor agonist plus a separate GIP receptor agonist — it is a single molecule engineered to activate both receptors. This dual mechanism is the defining characteristic of tirzepatide and the basis for its classification as a "twincretin."
Mounjaro and Zepbound: what's the difference?
| Brand | Active molecule | Approved use | Form |
|---|---|---|---|
| Mounjaro | Tirzepatide | Type 2 diabetes management | Weekly subcutaneous injection |
| Zepbound | Tirzepatide | Chronic weight management; obstructive sleep apnea in adults with obesity | Weekly subcutaneous injection |
The active molecule is identical. The difference is the approved indication — and, in practice, this affects insurance coverage and formulary access. The same tirzepatide molecule, the same weekly injection, the same side-effect profile. See: Ozempic vs Wegovy vs Mounjaro vs Zepbound.
How does tirzepatide compare to semaglutide?
The SURMOUNT-5 trial was the first direct head-to-head comparison of tirzepatide and semaglutide for weight loss. Participants on tirzepatide lost more body weight on average than those on semaglutide over the study period.
The dual mechanism — activating both GLP-1 and GIP receptors — is thought to explain this difference. But trial averages don't predict individual responses. Individual variation is real, and the right drug for you depends on your medical history, tolerability, cost, and access. See: Tirzepatide vs Semaglutide for Weight Loss.
Tirzepatide and sleep apnea
In December 2024, tirzepatide (Zepbound) became the first drug approved by the FDA specifically for moderate-to-severe obstructive sleep apnea in adults with obesity. This is a separate indication from its weight-management approval — based on the SURMOUNT-OSA trial, which showed large reductions in the number of breathing interruptions per hour during sleep. See: GLP-1s and Sleep Apnea: What to Know.
What about muscle loss on tirzepatide?
Tirzepatide suppresses appetite significantly, which reduces calorie intake and can lead to muscle loss alongside fat loss. The greater weight loss observed with tirzepatide compared to semaglutide may actually make muscle protection more — not less — important: more total weight lost means more at stake if protein intake is insufficient.
The approach is the same on tirzepatide as on any GLP-1: adequate protein (around 1.2–1.6g per kg of bodyweight per day), resistance training two to three times per week, and creatine. See: How to Keep Muscle While Losing Weight on a GLP-1.
Frequently asked
What is the difference between Mounjaro and Zepbound?
Both Mounjaro and Zepbound contain tirzepatide — the same active molecule. Mounjaro is approved for type 2 diabetes management. Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Same molecule, different brand name, different approved indication.
Is tirzepatide better than semaglutide?
In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide. This is useful data — but trial averages don't predict individual responses, and "better" depends on your medical history, tolerability, cost, and access. The right choice is a conversation with your clinician.
What is a GIP receptor agonist?
GIP (glucose-dependent insulinotropic polypeptide) is a gut hormone involved in insulin release and fat metabolism. A GIP receptor agonist activates the GIP receptor. Tirzepatide activates both the GIP receptor and the GLP-1 receptor — which is why it is described as a dual agonist.
Is tirzepatide approved for sleep apnea?
Yes. Zepbound (tirzepatide) received FDA approval in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This is a separate approval from its weight-management indication.
Does tirzepatide cause muscle loss?
Tirzepatide suppresses appetite significantly, which reduces calorie intake. Without adequate protein and resistance exercise, a meaningful share of the weight lost can be lean muscle. The greater weight loss associated with tirzepatide may actually make muscle protection more important. Adequate protein, resistance training, and creatine are the evidence-supported approach on any GLP-1.
Educational information only. This article does not diagnose, treat, cure or prevent any condition and is not medical advice. Decisions about which weight-loss or diabetes medication is right for you are a matter for you and your qualified healthcare professional.